Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Peloton

These businesses could be in trouble once the pandemic is over.

2 Expensive Stocks I'd Definitely Avoid

The biotech could potentially help to protect people from new coronavirus variants.

Here's Why Ocugen Stock Soared Today

MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, May 7, 2021.

Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update

Covid-19 vaccine candidate Covaxin may inhibit transmissions, and OCGN stock traders should appreciate the promising recent clinical results. The post Stick With Ocugen As Its Covid-19 Vaccine Is the Real Deal appeared first on InvestorPlace.

Stick With Ocugen As Its Covid-19 Vaccine Is the Real Deal

Vaxart

Ocugen Inc. (NASDAQ: OCGN) and Vaxart Inc. (NASDAQ: VXRT) are moving Monday. Ocugen shares gapped higher after the company's studies showed that COVAXIN is potentially effective against three key variants of SARS-CoV-2.

2 Biopharma Stocks Looking To Make A Difference Against COVID-19: Technical Levels To Watch

GT Biopharma Inc

Image Sensing Systems

Regional Health Properties

Penny stocks are hot right now and these former low-priced names are reaching for new highs this month. The post Former Penny Stocks To Watch Making New Highs In May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Former Penny Stocks To Watch Making New Highs In May 2021

Ocugen (OCGN) is likely to provide update related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports first-quarter 2021 results.

Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?

Shares of Ocugen jumped 20% on Monday after the biopharmaceutical company announced that its COVID-19 vaccine has shown signs of potential effectiveness against three variants of the virus. Covaxin, co-developed with Indian firm Bharat Biotech, demonstrated potential effectiveness against the variant of SARS-CoV-2 first discovered in Brazil.

Ocugen jumps 20% after its COVID-19 vaccine shows potential effectiveness against virus variants

Ocugen (OCGN) stock is soaring on Monday after announcing positive data concerning its Covaxin vaccine candidate for the novel coronavirus. The post OCGN Stock: The Big Study News Shooting Ocugen Shares Higher Today appeared first on InvestorPlace.

OCGN Stock: The Big Study News Shooting Ocugen Shares Higher Today

Shares of Ocugen Inc. were up 20.2% in trading on Monday after the Pennslyvania company said a COVID-19 vaccine it is contracted to develop with Indian biotechnology firm Bharat Biotech International Ltd. is "potentially" effective against B.1.1.28.2, or P.2.

Ocugen's stock is up after sharing preprint about COVID-19 vaccine effectiveness against lesser known Brazilian variant

Ocugen Inc (NASDAQ: OCGN) has announced that in a new study, COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2.  The study was conducted at the Indian Council of Medical Research (ICMR)-National Institute of Virology.

Ocugen Shares Gain After Its Partner's COVID-19 Vaccine Shows Effectiveness Against Multiple Variants

OCGN stock earlier seemed like a great play on a Covid-19 resurgence. But this narrative is not turning out so well.

If You Have Ocugen Stock, Now's the Time to Take Profits

MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. As previously disclosed, a study conducted by ICMR also suggested that COVAXIN was effective against the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617. It is notable that the Brazilian variant, B1.128.2, contains the E484K mutation that was found in New York.

Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2

The stock price of Ocugen Inc (NASDAQ: OCGN) increased from $12.67 to $13.11 (up 3.47%) this morning. This is why it happened.

OCGN Stock: From $12.67 To $13.11 (3.47% Increase) Pre-Market Explanation

Yet, there's little to indicate it will obtain FDA approval. In addition, there's plenty suggesting that the U.S., already oversupplied when it comes to vaccines, has little need for Covaxin.

Despite Covaxin News, Ocugen Stock Remains a Long-Shot for US Use

MicroVision

Skillz

Recent volatility in a handful of so-called meme stocks is putting the spotlight back on the tussle between individual investors and short sellers, months after a wild ride in GameStop captivated Wall Street's attention.

Analysis: New meme stocks swing as shorts and retail investors face off again

OCGN stock got a bump on Phase 3 results but was met with market skepticism following its subsequent strategic moves. The post The Reasons to Avoid OCGN Stock Keep Piling Up appeared first on InvestorPlace.

The Reasons to Avoid OCGN Stock Keep Piling Up

The stock price of Ocugen Inc (NASDAQ: OCGN) fell by over 2% pre-market. This is why it happened.

OCGN Stock: Over 2% Decrease Pre-Market Explanation

MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has closed the previously announced registered direct offering with healthcare-focused institutional investors for the sale of an aggregate of 10 million shares of its common stock at a purchase price of $10 per share.

Ocugen Inc. Announces Closing of $100 Million Registered Direct Offering of Common Stock Priced at a Premium to Market

Here's the Biggest Risk With Buying Ocugen Stock Right Now

Off and on the price chart, OCGN stock is setting itself up for big things that should have the attention of bullish investors. The post A Couple Of Shots in the Arm for Ocugen Stock appeared first on InvestorPlace.

A Couple Of Shots in the Arm for Ocugen Stock

Ocugen (NASDAQ:OCGN) had started initially trading as a penny stock for $0.28. However, after it announced a partnership with Bharat Biotech to commercialize its COVID vaccine in the U.S., its shares increased significantly.

Should You Buy Ocugen?

Ocugen's (NASDAQ:OCGN) stock has been falling Tuesday, down 9.75% to a price of $10.55. Tuesday the stock has been traded at a volume of 24.93 million, about 43.69% of its recent 30-day volume average of 57.06 million.

Why Ocugen's Stock is Down During Today's Session

Cenntro Electric Group

Zomedica

Bionano Genomics

Castor Maritime Inc

Why Ocugen, Zomedica, Naked Brand, and Other Reddit Stocks Soared Today

In this crazy Reddit-driven stock market, it's still important to understand why OCGN stock is hot. And why it's dangerous.

News for Ocugen, Inc. Stock (OCGN)